Ginkgo biloba. Indications, Mechanisms, and Safety.

Psychiatric Clinics of North America

Volumn 36, Issue 1, 2013, Pages 73-83

  Diamond, Bruce J ^a   Bailey, Mary R ^a  

^a WILLIAM PATERSON UNIVERSITY   (United States)

Author keywords

Alzheimer disease (AD); Anti platelet activating factor; Antioxidants; Cognitive impairment; Dementia; EGb 761; Ginkgo biloba

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; BILOBALIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLIC ACID; COUMARIC ACID; DIHYDROERGOTOXINE; FLAVONE DERIVATIVE; FLAVONOIDIC; FLAVONOL DIGLYCOSIDE DERIVATIVE; FLAVONOL MONOGLYCOSIDE DERIVATIVE; FLAVONOL TRIGLYCOSIDE DERIVATIVE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GLYCOSIDE; IBUPROFEN; MARFARIN; NICARDIPINE; NICERGOLINE; PLACEBO; ROFECOXIB; STEROID; TERPENE DERIVATIVE; TERPENOID DERIVATIVE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

ABDOMINAL PAIN; ADJUSTMENT DISORDER; ALLERGIC REACTION; ALZHEIMER DISEASE; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; APOPTOSIS; BLEEDING; BLOOD BRAIN BARRIER; BLOOD VISCOSITY; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN DYSFUNCTION; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMA; CONFUSION; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FATIGUE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GINKGO BILOBA; GLUCOSE METABOLISM; HAMILTON SCALE; HEART DISEASE; HEART INDEX; HEART PALPITATION; HEMATOMA; HERBAL MEDICINE; HUMAN; HYPERTENSION; HYPHEMA; INFLUENZA; INTERMITTENT CLAUDICATION; LOW DRUG DOSE; MEMORY DISORDER; MICROCIRCULATION; MOOD DISORDER; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; RETINA DISEASE; REVIEW; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TACHYCARDIA; TINNITUS; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE; VERBAL MEMORY; VERTIGO; VESTIBULAR DISORDER; VISUAL MEMORY; CEREBROVASCULAR DISORDERS; HERB DRUG INTERACTION;

CEREBROVASCULAR DISORDERS; DEMENTIA; HERB-DRUG INTERACTIONS; HUMANS; INTERMITTENT CLAUDICATION; PLANT EXTRACTS;

EID: 84875630494     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.12.006     Document Type: Review

References (17)

1. Diamond B.J., Shiflett S.C., Feiwel N., et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000, 81:668-678.
2. Ponto L.L., Schultz S.K. Gingko biloba extract: review of CNS effects. Ann Clin Psychiatry 2003, 15:109-119.
3. Kaschel R. Ginkgo biloba: specificity of neuropsychological improvement? A selective review in search of differential effects. Hum Psychopharmacol 2009, 24:345-370.
4. Johnson S., Diamond B.J., Rausch S., et al. The effect of gingko biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY) 2006, 2:19-24.
5. Woelk H., Arnoldt K., Kieser M., et al. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2007, 41:472-480.
6. Napryeyenko O., Sonnik G., Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci 2009, 283:224-229.
7. Vellas B., Coley N., Ousset P., et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012, 11:851-859.
8. Herrschaft H., Nacu A., Likhachev S., et al. Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 2012, 46:716-723.
9. McCarney R., Fisher P., Iliffe S., et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008, 23:1222-1230.
10. Singh V., Singh S.P., Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol 2010, 13:257-271.
11. Valli G., Giardina E.V. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 2002, 39:1083-1095.
12. Bressler R. Interactions between ginkgo biloba and prescription medications. Geriatrics 2005, 60:30-33.
13. Kellermann A.J., Kloft C. Is there a risk of bleeding associated with standardized ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011, 31:490-502.
14. Shi C., Liu J., Wu F., et al. Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice. Int J Mol Sci 2010, 11:107-123.
15. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009, 69:1777-1798.
16. Bent S., Goldberg H., Padula A., et al. Spontaneous bleeding associated with ginkgo biloba. J Gen Intern Med 2005, 20:657-661.
17. Williamson E.M. Drug interactions between herbal and prescription medicines. Drug Saf 2003, 26:1075-1092.